House Oversight — Estate records
HOUSE_OVERSIGHT_026761
Forbes Magazine SALSS Article Sep 9 2017
- Pages
- 3
- Text
- Searchable
Text as released
Machine-read from the scan. Names, dates and numbers can be misread — check anything you rely on against the original page.
Swedish American Group Focuses On Cancer, Autoimmune Diseases At... https://www.forbes.com/sites/genemarcial/2017/09/09/swedish-american... Investing / / #StockWatch SEP 9, 2017 @ 05:48 PM 729 12 Stocks to Buy Now Swedish American Group Focuses On Cancer, Autoimmune Diseases At Life Science Summit Gene Marcial, CONTRIBUTOR I have an insider's take on Wall Street FULL BIO Opinions expressed by Forbes Contributors are their own. Respected and acclaimed as rock stars in the arcane universe of life sciences, global scientists converged in Stockholm in late August this year for the annual Swedish American Life Science Summit (SALSS) meeting, where they unveiled and dissected revolutionary health care platforms. Among them are the use of robotics in surgery, how nanotechnology may make us "forever young,” applications of space technology in life sciences, and the “Moonshot” cancer program initiated by former Vice President Joseph Biden. Without doubt, global investors are closely watching organizations such as SALSS to discover the latest innovations and discoveries in life Shutterstock science. This area is replete with groups deeply involved in original research. So one of the major topics discussed at the SALSS conference was “impact investing,” or why investors should pay closer attention to investing in life science. “In today’s world with an aging population, we observe a higher occurrence of chronic diseases, such as cancer and autoimmune conditions,” noted Hans Straberg, chairman of Atlas Copco, and former CEO of Electrolux. “So Big Pharma and the industry are looking beyond the chemical and biologically derived molecules.” And as universities and small startups have taken the lead in R&D investments, "Big Pharma is very much dependent on collaborating with them, or acquiring their technologies,” he argued. Today Big Pharma has a “really strong position” in life sciences and are Looking for "new blockbusters to replace current stars that are coming off-patent," h […]